  
 
1  
   
 
CURRICULUM VITAE 
  
 
1.  PERSONAL DETAILS: 
 
Full Name: Yaacov Baruch 
 
 
2.  ACADEMIC DEGREES: 
 
1977 M.D., Faculty of Medicine, Technion-Israel Ins titute of Technology, Haifa. 
  
 
3. ACADEMIC  APPOINTMENTS : 
 
2002-
Present Clinical Associate professor, Liver Unit, Bruce Rap paport Faculty of Medicine, 
Technion-Israel Institute of Technology, Haifa.  
  
2005-2006 Associate visiting professor, Department of medicine, Division of 
Gastroenterology, University of Texas, Houston, USA . 
  
2002 Visiting professor – Winnipeg health science center (Canada).  
  
1996- Clinical senior lecturer, Department of Inter nal Medicine, Bruce Rappaport 
Faculty of Medicine, Technion-Israel Institute of T echnology, Haifa. 
  
1995 Visiting professor at the university of Manitoba (C anada).  
  
1991- Clinical lecturer, Department of Internal Med icine, Bruce Rappaport Faculty of 
Medicine, Technion-Israel Institute of Technology, Haifa. 
  
1986- Clinical instructor, Department of Internal M edicine, Bruce Rappaport Faculty of 
Medicine, Technion-Israel Institute of Technology, Haifa. 
  
4.  PROFESSIONAL EXPERIENCE : 
 
1995-present Director, Liver Unit, Rambam Medical C enter, Haifa. 
  
2012 Medical advisor to Coeruleus Ltd.  
  
2005-2006 Senior Transplant Hepatologist and Gastro enterologist, Division of 
Gastroenterology and Nutrition, Herman Memorial Hos pital, Houston, Texas. 
  
1986-2000 Deputy head, Department of Medicine B, Ra mbam Medical Center, Haifa. 
  
1986-1995 Head, follow-up clinic for patients after  liver transplant, Rambam Medical 
Center, Haifa. 
1988 - Special training in intravenous liver biopsy , Beaujon Hospital, Clichy, France. 
  
1986-1988 Experience with gastrointestinal endoscop y, including endoscopic retrograde 
cholangiography.   
2  
   
1983-1988 Residency in Gastroenterology, Rambam Med ical Center, Haifa. 
  
1987 -  Two months' clinical experience in long-ter m treatment of patients after liver 
transplant, Presbyterian-University Hospital, Pitts burgh, Pennsylvania, U.S.A. 
  
1983-1985 Research fellowship, Liver and Gastrointe stinal Units, Groote-Schuur Hospital, 
University of Cape Town, South Africa. 
  
1978-1983 Residency in Internal Medicine, Rambam Me dical Center, Haifa. 
  
1977-1978 Internship, Hadassah Medical Center, Jeru salem. 
  
 
Qualifying examinations passed 
 
1990 -  Israel Board of Gastroenterology.  
  
1983 -  E.C.F.M.G. (Educational Commission for Foreign Medi cal Graduates).  
  
1982 - Israel Board of Internal Medicine.  
 
5.  RESEARCH  INTERESTS: 
 
1989-present Head of the Laboratory for Liver regen eration medicine, Bruce Rappaport 
Faculty of Medicine, Technion-Israel Institute of T echnology, Haifa.  
 
1983-1985 Research in Liver Research Laboratory,  University of Cape Town, South 
Africa.  Liver Regeneration and specific growth factors.  
  
1981-1983 Research in Lipid Research Laboratory, Rambam Medic al Center, Haifa. 
Hyperlipidemia In Primary Biliary Cirrhosis.  
 
6.  TEACHING EXPERIENCE:  
 
1998- present 
 Bruce Rappaport Faculty of Medicine, Technion-Israe l: Coordinator of the 
integrative Course of gastrointestinal and liver di seases.  
  
1998- present TeAMS- Technion American Medical Scho ol Program: Coordinator of the 
ICM- Introduction to clinical medicine. 
  
1986- present Course coordinator – Liver diseases f or students in Internal medicine wards.   
  
1986-1991 Rambam Medical Center, Haifa:  Course coordinator, Internal Medicine for  
Primary Care Physicians.  
  
1980- 1991 Bruce Rappaport Faculty of Medicine, Technion -Israel Institute of Technology:  
Instructor and coordinator, course in Internal Medi cine. 
  
1978-1981 Bruce Rappaport Faculty of Medicine, Tech nion-Israel Institute of Technology: 
Instructor, course on Physical Diagnosis to medical  students. 
 
7.  TECHNION  ACTIVITIES: 
   
3  
 2011-Present Strategic Convergence Committee , Faculty of  Medicine, Technion. 
  
1999-2005 Animal House Committee, Faculty of Medicine, Techni on.  
  
1999-2001 Member of the MD thesis committee.  
  
1993-1999 Admissions Committee, Faculty of  Medicine, Technio n.  
  
1986-1996 Animal House Committee, Faculty of Medicine, Techni on.  
 
   
8.  DEPARTMENTAL  ACTIVITIES: 
 
 
9. PUBLIC PROFESSIONAL ACTIVITES:  
 
2012- Member of the Israel committee for HCV treatment guide line.  
  
2011- Head of appeal committee for liver transplantation at the ministry of health.  
  
1996-2011 Member of the board of governors of the Israel foun dation for liver disease.  
  
2008-  2009 Member of "The Health Basket" committee of IMA.  
  
1996-2007 Head of the Liver transplantation committee at t he Israel council of 
transplantation.  
  
1993-2005 Member of the Liver Transplant Committee advisory t o Israel Transplantation  
Council (Since 1994, head of committee).  
  
1996-2000 Member of the Council for Quality at Rambam Medical  Center, and Head of a 
Quality Improvement project on pulmonary edema.  
  
1997-1999 Chairman of the Israel association for the study of  the liver.  
  
1991-1993 Head, Medical Archives Committee, Rambam Medical Center.  
  
1989-1993 Hospital Mortality Committee, Rambam Medical Center .  
 
Reviewer of International Journals  
 
1999 Journal of  Hepatology  
2001 Liver  
2001 Journal Clin Endocrinol Metab  
2003  Journal of Gastroentrol and Hepatol  
2004  Journal of Anti Cancer Drugs  
2006 Hepatology  
2007 European Journal of Gastroenterol and hepatol 
2008 Journal cell physiology  
2008 Journal clin and lab investigation  
2009 Journal of molecular and cellular med  
2010 Journal of  Histology and Histopathology  
2010 Rambam Maimonides Medical Journal  
2011 Histochemistry and Cell Biology    
4  
 2011 DDS  
2012 Journal of Laboratory Investigation  
2012 Journal of International Hepatology  
 
Editorial board: 
 
2008 Liver International  
2011 Current Tissue Engineering  
2012 Editor of the Israeli Journal for Liver disease s (Herefuah Update) . 
 
10.  MEMBERSHIP IN PROFESSIONAL SOCIETIES: 
 
National:  
 
 Israel Gastrointestinal Association. 
 Israel Association for the study of the liver (IASL ). 
 Israel Association for Organ Transplantation. 
International: 
 European Association for the Study of the Liver. 
 American Association for the Study of the Liver. 
 International Liver transplantation association.  
 International Association for the study of the live r 
 
11.  HONORS: 
 
1992 American Physicians Fellowship and Dean of Faculty Award for Excellency in research.  
 
 
12.  GRADUATE STUDENTS: 
 
PhD, and MSc 
 
Finished 
2004 Rubinstein Iris, PhD. Co -culture of hepatocytes and Kuppfer and Ito cells on   
biodegradable sponges for liver cell support. (with  Prof. Smadar Cohen, primary 
supervisor, BGU).  
  
2004 Shani Hagit, MSc. Enhancement of transplanted liver  cell engraftment during liver 
regeneration in the rat. (Prof. Yaacov Baruch prima ry supervisor).  
  
2007 
 Boyanjo Ilanit, MSc. Human embryonic stem cells dif ferentiation during liver 
regeneration in the rat. (Prof. Yaacov Baruch prima ry supervisor).  
  
2008 Helena Axelman, MSc. Enhancement of transplanted li ver cell engraftment during  
 liver regeneration in the rat, with vascular manip ulations.(Prof. Yaacov Baruch  
primary supervisor).  
 
Expected to finish 
  
2010-2012 Omri Nayshool MSc. Hydrogel scaffolds for liver tis sue bioengineering.  
(Prof. Yaacov Baruch primary supervisor).    
5  
  
MD thesis 
 
1. Igal Peled, 1989: The effect of calcium channel blo ckers on liver regeneration in the rat.  
Supervisors  
  
2. Shirley Nesher, 1990:  Hepatitis C virus in liver c irrhotic patients in Israel.  
  
3. Barak B, 1990: Sexual transmission of HCV infection. (Joint supervision with Prof. Ben - 
Porath).  
  
4. Sigal Rubin, 1996: Amantadine in HCV Chronic liver disease.  
(Joint supervision  with Dr. Assy Nimer and Prof. R afael Enat).  
  
5. Konofeniki Muriel, 2002: Pain mapping after liver b iopsy to improve patients’ care and 
compliance. (Joint supervision with Dr. Aisenberg A .).  
  
6. Mayson Darawshi, 2012: Can histomorphometric findin gs predict response to antiviral 
therapy in patients with chronic HCV infection?  
  
7. Nizar Higazi, 2013: Evaluation of early stage fibro sis in patients with chronic HCV infection 
using digital imaging. 
 
Basic science  
 
1. Nimer Assy, 1996: IGF -I generation test in patients with liver cirrhosis.  
(Joint supervisor with Z. Hochberg and T.  Amit.).  
  
2. Sabith Wissam, 1995:  Long -term effect of growth factor -binding Factor on regenerating  
rat liver or parenchymal and non-parenchymal cells.    
(Joint supervisor with G. Shoshany.).  
  
3. Ana Salomonov, 1995:  Factors predicting response t o interferon Treatment in Israeli  
patients with hepatitis C virus. (Supervision).  
  
4. Krasik Ana, 1996: VEGF and the liver. Use of transf ected Fibroblasts with VEGF gene 
in the nude mice model. (Supervision).  
  
5. Prodjansky J, 1999: IGF -I generation test in patients with liver cirrhosis.    
(Joint supervision with Z. Hochberg and Assy Nimer) .  
  
6. Weitzman E, 2000: Detection of Sry - domain of the Y -chromosome as a marker of 
transplanted liver  cells. (Supervision).  
  
7. Armali Z, 2002: Diuresis with vassopressin in -patients with tense ascites.  
(Joint supervision with Dr. Eisenmam).  
  
8. Weisbuch F. 2004, Liver tissue Bioengineering.  
  
9. Farber Y, 2003: Correlation between Esophageal X-rays and UGIT endoscopy for the 
detection of varices in liver cirrhosis patients (J oint supervision with Prof. Eliakim).  
  
10. Saadi  T, 2008:  Hepatocytes function within Biosynthetic p olymers.  
 
11. Bramnik Z, 2010:  Transplantation of hepatocyte s and biosynthetic hydrogel scaffolds, 
into rat’s liver after 70% hepatectomy, the basis f or liver tissue regeneration therapy.    
6  
   
12. Ori Kaplan, 2012: Intravascular liver tissue bi oengineering.  
 
13.  RESEARCH GRANTS: 
 
2008-  Joint Inter departmental grant with Bioengin eering, Technion-Israel Institute of 
Technology. Biosynthetic hydrogel scaffolds for liv er tissue regeneration 
therapy. (25,000 IS).  Prof. Baruch Y. (PI) and Dr.  Seliktar D. (PI).  
  
2006- Ministry of health research grant from Inheritance funds : Stem cell  
Transplantation (80,000 IS). Dr. Weitzman E. (PI), Prof. Baruch Y. (PI).  
  
2002- Israel ministry of health  (100,000 IS). Human stem  cells in the SCID mice 
regenerating liver. (With Prof. Itzkovitz). (PI): D r. Weitzman and Prof. Baruch.  
  
2001- Mars -Pittsburgh fund (25,000$). VEGF and hepatocytes tra nsplantation. Prof. Y. 
Baruch (PI ) and Prof. G. Neufeld.  
  
2000- Ministry of health research grant from Inheritance funds: Liver cell 
transplantation (18,000 IS). Prof. Y. Baruch (PI).  
  
1999- Israel ministry of health (60,000 IS). Tissue Bioen gineering for liver failure  
supports. Prof. Y. Baruch (PI) and Prof. Smadar Cohen (PI) fr om B.G.U.  
  
1999- Israel ministry of health (60,000 IS). Vasopressin in fluid retention in liver 
Cirrhosis and C.H.F. Dr.Eisenman (PI). Prof. Y. Bar uch (PI).  
  
1998-  Niedersachsen - Technion grant (200 000 DM). Tissue Bioengineering for liver 
failure support. (Prof. Y. Baruch (PI) , prof. G. S pira (PI), Prof. Smadar Cohen 
(PI) and Prof. Giuliano Ramadori from Gottingen (PI ))  
  
1994-  Joint grant from Israel Ministry of Health and Tech nion -Israel Institute of 
Technology: (15000 IS). Effect of ursodeoxycholic a cid on cardiovascular 
system in liver cirrhosis (Prof. Y. Baruch (PI). In  collaboration with Dr. N. Assy 
and Prof. A. Bomzon.  
  
1990-1992 Israel Ministry of Health (15,000 IS). Liver regene ration and growth stimulation.  
Prof. Y. Baruch (PI), in collaboration with Prof. M . Fry, Dept. of Biochemistry. 
Technion).  
 
14.  SIGNIFICANT PROFESSIONAL PROJECTS: 
 
2001  Efficacy and safety of  budesonide capsules versus prednisone patients with  diagnosis of active 
autoimmune hepatitis. A double randomized active co ntrolled multi center phase III study (RAFA 
BUC -38).  
   
2002  A Preliminary assessment of safety and antiviral ac tivity of open -label  Entecavir in subjects with 
chronic hepatitis B following monotherapy in other Entecavir trials (BMS AI463 -901).  
   
2003  Ribavirin with Peg interferon in chronic hepatitis C patients (ROCHE ML16837)  
   
2003  Entecavir for subjects with chronic hepatitis B inf ection (BMS AI463 -900) . 
   
2003  Long -term assessment of treatment outcomes with Entecavi r and Lamivudine for chronic hepatitis B 
infection in patients who have enrolled  in phase III Entecavir trials (BMS AI463 -049).  
   
2005  Randomized, Double -Blind, Multicenter study to compare the safety and efficacy of Viramidine to 
Ribavirin in treatment –naïve patients with chronic hepatitis C (VALIANT RN A003142 -302) .   
7  
    
2005  A Randomized, Double -Blind Trial of Telbivudine versus Lamivudine in adu lts with decompensated 
chronic hepatitis B and evidence of Cirrhosis (QUIN TILES NV -02B -011).  
   
2006  A Randomized Trial of Switching Antiviral Therapy f orm Lamivudine to Telbivudine. Continued 
Lamivudine Treatment in adults with Chronic Hepatit is B (QUINTILES  NV-02B-019). 
   
2006  A Double -Blind, Randomized, Multi -Centre, PhaseIIA parallel dose ranging study to ass ess the 
anitfibrotic of GI26570 in HCV infected individuals  who have failed standard antiviral therapy and 
who have documented hepatic fibrosis ISHAK grade 2 -5 (GSK GI262570).  
   
2006  A Multi -Center, Active -Controlled, Randomized, Open -Label Study to Evaluate the safety, 
Tolerabillty, and Efficacy of Albuferon Recombinant  Human Albumin-Interferon Alfa Fusion Protein 
in Combination with Ribavirin in Interferon Alfa Na ïve Subjects with Chronic Hepatitis C Genotype 
1 (PAREXEL  ALFR -HC -04).  
   
2006  An open label trial of Telbivudine in adults with c hronic hepatitis B previously treated in Telbivudine 
studies (QUINTILES  NV -02B -022).  
   
2008  A phase II randomized, placebo -controlled study to evaluate the safety and efficac y of MK -7009 
administered concomitantly with Pegylated Interfero n and Ribavirin for 28 days in treatment naïve 
patients with chronic hepatitis C infection (MSD pr otocol 007).  
   
2009  A randomized, double -blind, placebo -controlled phase III trial of telaprevir with pegyl ated interfron 
alfa 2a and ribavirin in subjects eith genotype 1 c hronic hepatitis C infection who did not achieve 
sustained virologic response following prior treatm ent with pegylated interferon plus ribavirin (J & J  
VX950 -TiDP24).  
   
2009  A Phase II Open Label Study of   MK-7009  Administered Concomitantly  with Pegylated Interferon 
Alfa-2a and Ribavirin to Patients with Chronic  Hepatitis C Infection After Participation in Other MK-
7009 Clinical Trial (MSD 028-00). 
   
2009  A phase II randomized, plecebo-controlled study to Evalute the safety and Tolerability, and Efficacy 
of different Regiments of MK-7009 When Administered  concomitanty with Pegyleted Interferon and 
Ribavirin in Treatment-Naïve Patients With chronic Genotype 1 Hepatitis C Virus Infection (MSD 
019-00). 
   
2009  A phase Iib, randomized, double-blind,  plecebo-con trolled trial to investigate the efficacy, 
tolerability, safety and pharmacokintics of TMC435 as part of treatment regimen including PegIFN 
alfa-2a and ribavirin in HCV genotype 1 infected su bjects who failed to respond or relapsed 
following at least 1 cours of PegIFN alfa-2a/b and RBV therapy (J & J TMC-435-TiDP16-C206). 
    
2009  An Open-Label, multi-center study evaluating the ef ficacy , safety and tolerability of extended 
treatment of Pegasys in combination with Copegus in  genotype 1,2 and 3 chronic hepatitis C patients 
defined as slow responders/non RVR (ROCHE ML21778).  
    
2010  A Phase 3, randomized, double-blind,  plecebo-contr olled trial of 48 weeks of GS-9190 in 
combination with Peginterferon Alfa 2a and Ribaviri n in previously untreated subjects with genotype 
1 chronic hepatitis C virus infection (PPD – GILEAD  GS-US-196-0116). 
   
2010  A Phase II, multicenter, randomized, double blind, placebo controlled study on the effect of 
Aramchol on liver triglyceride concentration in pat ients with steatosis due to NAFLD or NASH  
(Galmed  Aramchol 003) 
   
2010  An open-label, single-arm, roll-over trial of telap revir in combination with pegylated interferon alfa -
2a (Pegasys®) and ribavirin (Copegus®) for subjects  from the control group of the VX-950-TiDP24-
C216 trial who failed therapy for virologic reasons  (Tibotec VX-950-TiDP24-C219).  
     
8  
 2010  Pharmacogenomic analysis of Blood samples to Identi fy Host Genomic profiles that segregate 
responders from Non-responders following treatment with Peg-Interferon and Ribavirin in HCV 
infected subjects -genotype 1 (CATO PJMR0012106).  
   
2010  A Phase II randomized, multicenter, open-label stud y of TG4040 (MVA-HCV) in combination with 
pegylated interferon alfa-2a and ribavirin versus p egylated interferon alfa-2a and ribavirin in 
treatment –naïve patients with chronic genotype 1 h epatitis C (Transgene TG4040).  
   
2011  Double-blind, randomised, placebo-controlled, multi -centre phase III clinical study comparing the 
combination of ursodeoxycholic acid capsules plus b udesonide capsules to ursodeoxycholic acid 
capsules plus placebo in the treatment of primary b iliary cirrhosis (Dr. Falk Pharma GmbH BUC-
56/PBC). 
   
201 1 A Randomized, Active-Controlled, Dose-Ranging Estim ation Study to Evaluate the Safety, 
Tolerability, and Efficacy of Different Regimens of  MK-5172 When Administered Concomitantly 
with Peginterferon alfa-2b and Ribavirin in Treatme nt-Naive Patients with Chronic Genotype 1 
Hepatitis C Virus Infection (Merck & CO., MK-5172).  
   
2011  A Phase 3b Study of 2 Treatment Durations of Telapr evir, Peg-IFN and Ribavirin in tratment-naïve 
and prior relapser subjects with genotype 1 chronic  hepatitis c and IL28B cc genoytpe (Vertex 
Pharmaceuticals VX11-950-114). 
   
201 2 A Phase 2, Randomized, Multicenter, Placebo-Control led, Double-Blind, Parallel grope study, with 
an open label extension to evaluate the efficacy, s aftey and Pharmacokinetics of E5501 in subjects 
with chronic hepatitis c virus related Thrombocytop enia who are patential candidates for antiviral 
treatment (Eisai Inc. E5501). 
   
201 2 A Phase III, randomized, double -blind, placebo -controlled study to investigate the efficacy, safet y 
and tolerability of TMC435 vs. placebo as part of a  treatment regimen including peginterferon alfa-2a 
and ribavirin in hepatitis C, genotype 1 infected s ubjects who relapsed after previous interferon-base d 
therapy (Tibotec.  TMC435HPC 3007).  
   
201 2 Double-blind, randomized, placebo controlled study to assess the safety and the efficacy of a 
sublingual administration of Flumazenil to reverse the effect of hypnotic drugs (Zolpidem or 
Brotizolam) in healthy adults (Coeruleus Ltd . CRLS001). 
  
2012  A Phase 3 Study with Asunaprevir and Daclatasvir (D UAL) for Null or Partial Responders to 
Peginterferon Alfa and Ribavirin (P/R), Intolerant or Ineligible to P/R Subjects and Treatment - 
Naive Subjects with Chronic Hepatitis C Genotype 1b  Infection (Bristol-Myers Squibb AI452-028). 
  
201 2 A Phase II Randomized, Partially Blinded, Pilot Stu dy to Evaluate the Efficacy and Safety of MK-
5172 in Combination with Ribavirin (RBV) in Treatme nt-Naive (TN) Patients with Chronic 
Genotype 1 (GT 1) Hepatitis C Virus Infection (Merc k & CO. Inc. MK-5172-034). 
   
2012  A Phase 3, Safety and Efficacy Study of Boceprevir/ Peginterferon Alfa-2a/ribavirin in Chronic HCV 
Genotype 1 IL28B CC Subjects (Merck & CO. Inc. MK 3 034-040). 
   
 
 
 
 
2012  A Long-Term Follow-up Study to Evaluate the Durabil ity of Virologic Response and/or Viral 
Resistance Patterns of Subjects With Chronic Hepati tis C Who Have Been Previously Treated with 
MK-5172 in a Prior Clinical Trial (Merck & CO. Inc.  MK 5172-017). 
  
2012  A Phase II Randomized Clinical Trial to Study the E fficacy and Safety of MK-5172 in Combination 
with Ribavirin (RBV) in Subjects with Chronic Hepat itis C Virus Infection.  (Merck & CO. Inc. MK   
9  
 5172-039). 
  
2012  A Randomized, Double-Blind, Controlled Study to Eva luate the Efficacy and Safety of the 
Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r /ABT-267) and ABT-333 With and 
Without Ribavirin (RBV) in Treatment-Naïve Adults w ith Genotype 1b Chronic Hepatitis C Virus 
(HCV) Infection (PEARL-III) . (Abbott M13-961). 
  
2012  A Phase 3, Multicenter, Randomized, Active-Controll ed study to investigate the safety and efficacy 
of PSI-7977 and ribavirin for 12 weeks compared to Pegylated interferon and Ribavirin for 24 weeks 
in treatment Naïve patients with chronic genotype 2  or 3 HCV infection (Quintiles P7977-1231). 
  
2013  A Study of the Combination Regimen MK-5172, MK-8742 , and Ribavirin in Participants With 
Chronic Hepatitis C  (Merck & CO. Inc. MK 5172-035) . 
  
2013  A Phase 3 Blinded Randomized Study of Peginterferon  Lambda-1a and Ribavirin Compared to 
Peginterferon Alfa-2a and Ribavirin, Each Administe red with Telaprevir in Subjects with Genotype-1 
Chronic Hepatitis C who are Treatment-naïve or Rela psed on Treatment with Peginterferon Alfa and 
Ribavirin (Bristol-Myers Squibb AI452-020). 
  
2013  A Phase II Clinical Trial to Study the Efficacy and  Safety of a combination regimen of MK-5172 and 
MK-8742 with Ribavirin (RBV) in Subjects with Chron ic Hepatitis C Genotype 2 (Merck & CO. Inc. 
MK 5172-047). 
  
2014  A Phase II/III Randomized Clinical Trial to Study t he Efficacy and Safety of the Combination 
Regimen of MK-5172 and MK-8742 in Subjects with Chr onic Hepatitis C Virus Infection and 
Chronic Kidney Disease (Merck & CO. Inc. MK 5172-05 2). 
  
2014  A Randomized, Global, Double-blind, Placebo-control led, Parallel-group Study to Evaluate the 
Efficacy and Safety of Once-daily Oral Avatrombopag  for the Treatment of Adults with 
Thrombocytopenia Associated with Liver Disease Prio r to an Elective Procedure (Eisai Inc.  E5501-
G000-311) 
  
2014  A Phase II Clinical Trial to Study the Efficacy and  Safety of the combination regimen of 
MK-5172 + MK-8742 + Ribavirin (R) in Subjects with Chronic Hepatitis C Virus Infection  
who failed prior Direct Acting Antiviral Therapy (M erck & CO. Inc. MK5172-048). 
  
2014  A Phase III Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen 
of  MK-5172/MK-8742 in Treatment-Naïve Subjects wit h Chronic HCV GT1, GT4, GT5, and GT6 
Infection who are Co-Infected with HIV (Merck & CO.  Inc. MK5172-061). 
  
2014  Multicenter, Randomized Phase 2B Study to Evaluate the Efficacy, Safety and Tolerability of OCR-
002 (ornithine phenylacetate) in Hospitalized Patie nts with Cirrhosis and Associated 
Hyperammonemia with an Episode of Hepatic Encephalo pathy (STOP-HE Study, OCR002-HE209). 
  
2014  Phase IIb, double blind randomized, controlled clin ical trial, to evaluate the efficacy and safety of two 
Aramchol doses versus placebo in patients with Non- Alcoholic Steatohepatitis (NASH, Aramchol05) 
  
2014  An Open-Label, Multicenter Study to Evaluate Long-T erm Outcomes With ABT-50/Ritonavir/ 
ABT-267 (ABT-450/r/ABT-267) and ABT-333 With orWith out Ribavirin (RBV) in Adults With 
Genotype 1 Chronic Hepatitis C Virus (HCV) Infectio n (TOPAZ-I, M14-423). 
  
2014  A Phase II, Randomized, Open-Label Clinical Trial t o Study the Efficacy and Safety of the 
Combination Regimen of MK-5172 and MK-3682 with Eit her MK-8742 or MK-8408 in 
Subjects with Chronic HCV GT3 Infection (MK3682-012 ). 
  
2014  A Phase II, Randomized, Open-Label Clinical Trial t o Study the Efficacy and Safety of the 
Combination Regimen of MK-5172 and MK-3682 with Eit her MK-8742 or MK-8408 in   
10  
 Subjects with Chronic HCV GT1, GT2, and GT4 Infecti on (MK3682-011). 
  
      
15.  PUBLICATIONS 
 
M.D. Thesis 
 
1. Baruch Y .  Disappearance of Q wave from electrocardiogram o f patients after myocardial  
Infarction.M.D. thesis, Technion -Israel Institute of Technology, Haifa, 1977.  
 
Original Articles 
 
Basic Research 
 
2. Baruch Y , Brook JG, Eidelman S, Aviram M.  Increased concentration of high density  
lipoprotein in plasma and decreased platelet aggreg ation in primary biliary cirrhosis.  
Atherosclerosis 53:151 -162, 1984.  
  
3. Yeshurun D, Aviram M, Barak C, Baruch Y , Brook JG.  Effect of prolonged fasting on lipid  
and lipoprotein concentrations in markedly obese pa tients.  Nutr Rep Int 34:613 -619, 1986.  
  
4. Baruch Y , Frith, Kirsch RE.  Twenty -two percent partial hepatectomy: in vivo rat model for  
the study of  liver regeneration.  J Hepatol 12:3 16 -320, 1991.  
  
5. Liang TJ, Baruch Y , Ben -Porath E, et al.  Hepatitis B and hepatitis C virus  infection in patients 
with idiopathic liver disease.  Hepatology 13:1044 -1051, 1991.  
  
6. Baruch Y , Amit T, Enat R, Hertz P, Youdim MBH, Hochberg Z.  Growth hormone binding  
protein in liver cirrhotic patients.  J Clin Endocr inol Metab 73: 777 -781, 1991.  
  
7. Baruch Y , Enat R, Gershoni -Baruch R, et al. Anamnestic response to hepatitis B vaccine in  
Non-Alcoholic liver cirrhosis patients with and wit hout HBV-DNA.   
Am J Gastroenterol 87:613 -616, 1992.  
  
8. Amit T, Hartman K, Shoshany G, Baruch Y , Youdim MBH, Hochberg Z.  The turnover of  
Growth hormone (GH) binding protein and GH receptor  in rabbit and rat.  
Mol Cell Endocrine 94:149 -154, 1993.  
  
9. Baruch Y , Amit T, Enat R, Shoshany G, Youdim MBH, Hochberg Z. Growth  hormone -binding 
protein in partially hepatectomized rats.  Horm Res  40:173 -177, 1993.  
  
10. Gilhar A, Enat R, Baruch Y .  HLA -DR -positive Langerhans cells in liver cirrhosis and 
Immunosuppressed liver -transplanted patients.  Acta Dermato -Venereol 74:93 -94, 1994.  
  
11. Baruch Y , Shoshany G, Neufeld G, Enat R.  Basic fibr oblast growth factor is hepatotropic for  
rat liver in regeneration.  J Hepatol 23:328 -332, 1995.  
  
12. Assy N, Hochberg Z, Amit T, Enat R, Baruch Y . Growth hormone stimulated insulin -like  
growth factor I and insulin binding protein 3 in li ver cirrhosis.  J Hepatol  27: 797 -802, 1997.  
  
13. Assy N, Hochberg Z, Enat R, Baruch  Y. Prognostic value of of GH -stimulated IGF -I  and     
IGFBP -3 in compensated and decompensated liver cirrhosis.  Dig Dis Sci. 43:1317 -1321, 1998.  
  
14. Baruch Y , Assy N, Amit T, Kr ivoy N, Strikovsky D, Shen -Orr Z Hochberg Z. Spontaneous  
Pulsatility and pharmacokinetics of growth hormone in liver cirrhotic patients.  
J Hepatol 29: 559 -564, 1998.  
  
15. Assy N, Spira G, Paizi M, Shankar L, Kraizer Y, Coh en T, Neufeld G, Enat R, Baruch Y .  
Effect of vascular endothelial growth factor on hep atic regenerative activity following partial    
11  
 Hepatectomy in rats. J Hepatol 30: 911 -915, 1999.  
  
 
16. Weitzman E, Shenkar L, Shoshany G, Kasinetz L, Gers honi - Baruch R, Baruch Y .  
Detection of transplanted Hepatocytes by PCR analys is of the SRY domain on the Y chromosome. 
Transplant Proceed 32: 721 -723, 2000.  
  
17. Baruch Y , Neubauer K, Shenkar L, Wilfling T, Ritzel A, Bouc holt M, Ramadori G.   
Von willebrand factor (vWf) expression and plasma l evels after partial hepatectomy (PHP) in the 
rat. J Hepato 37 (4): 471 -477, 2002.  
  
18. Neubauer K, Baruch  Y, Lindhorst A, Saile B, Ramadori G. Gelsolin gene e xpression is upregulated 
in damaged rat and human livers within non-parenchy mal cells and not in epatocytes. Histochem 
Cell Biol 120: 265-275, 2003.  
  
19. Perets A, Baruch Y , Shoshany G, Weisbuch F, Neufeld G, Cohen S.  
Enhancing the vascularization of 3-D porous alginat e scaffolds by incorporating controlled release 
bFGF microspheres. J Biomed Mater Res 65A:489 -497, 2003.  
  
20. Shani H, Tsiperson V, Shoshany G, Veitzmen E. Neufe ld G, Baruch Y .  
The effect of VEGF on hepatocyte engraftment after intrasplenic cell transplantation in the rat. 
Cell transplantation 14:49 -57, 2005.  
  
21. Vadasz Z, Kessler O, Akir G, Gengrinovitch S, Kagan  H.M, Baruch Y , Ben Izhak O, and Neufeld 
G. The role of lysyl oxidase related protein-1 in t he pathogenesis of liver diseases associated with 
copper accumulation. Journal of Hepatology. 43:499 -507, 2005.  
  
22. Tsiperson V, Goldshmidt O, Ilan  N, Shoshany G, Vlodavsky I, Veitzman   E and Baruch  Y. 
Heparanase enhances hepatocytes engraftment in part ially hepatectomysed rats.  
Tissue Engineer. 14:449 -455, 2008.  
  
23. J. Carmel, A. Arish, G. Shoshany and Baruch Y.  
Heparanase accelerates proliferation of both hepato cytes and sinusoidal endothelial cells after 
partial hepatectomy despite IL-6 and TNF-a down reg ulation. Experimental and Molecular 
Pathology. 92: 202-209, 2012. 
  
24. Saadi T, Nayshool O, Carmel J, Ariche A, Bramnik Z,  Mironi-Harpaz I, Seliktar D, Baruch 
Y. Cellularized biosynthetic micro-hydrogel polymers , for intravascular liver tissue 
regeneration therapy. Tissue Eng Part A. 20: 2850-2 859, 2014. 
  
Clinical Descriptive Research 
 
25. Markiewicz W, Monakier I, Brik A, Baruch Y , Hir J. Clinical echocardiographic correlations in  
pericardial effusion.  Eur Heart J 3:260 -266, 1982.  
  
26. Enat R, Ben -Porath E, Joffe B, Baruch Y , Lichtig C.  Ethnic differences in the incidence of 
postnecrotic cirrhosis in Israel: correlation with hepatitis B virus serological markers.  
Am J Gastroenterol 78: 656 -660, 1983.  
  
27. Gershoni -Baruch R, Baruch Y , Viener A, Lichtig C.  Fechtner syndrome: clinical a nd genetic  
Aspects. Am J Med Genet 31:357 -367, 1988.  
  
28. Baruch Y , Ben -Arie Y.  Kerner H, Lorber M, Best L -A, Gershoni -Baruch R. Giant lymph node  
Hyperplasia (Castleman's disease): a clinical study  of eight patients.   
Postgrad Med J  67:366 -370, 1991.  
  
29. Blumenfeld Z, Enat R, Brandes JM, Baruch Y .  Dysfunctional bleeding   in women after liver  
Transplantation: use of GnRH analogue.  Fertil Ster il 57:1121 -1123, 1992.    
12  
   
30. Baruch Y , Engel A, Eyal A, Enat R.  Transjugular liver biop sy in patients with bleeding tendency.  
Harefuah 125:461 -463, 1993 (in Hebrew).  
  
31. Modan B, Shpilberg O, Baruch Y , Sikuler E, Anis E, Ashur Y, Chetrit A, Luxenburg O, Rosenberg 
E, Rosenthol N, Sadetzki S, Benaim H, Eckstein H, S houval D.  The need for liver Transplantation: 
a nationwide estimate based on consensus review.  L ancet 346:660 -662, 1995.  
  
32. Ilan Y, Galun E, Nagler A, Baruch Y , Livni N, Shouval D, Tur -Kaspa R. sanctuary of hepatitis B 
virus in bone-marrow cells of patients undergoing l iver transplantation. Liver Transpl Surg 2:206-
210, 1996.  
 
33. Assy N, Blumenfeld Z, Berkovitz D,  Nave Y, Kramsky  R, Rosenthal E, Enat R, Baruch Y .  
Long term follow up of liver transplant patients  i n a non liver transplantation Center.  
Transplant Proceed  29:2664 -2666, 1997.  
  
34. Baruch Y,  Assy N, Kramsky R, Enat R. Safety of conversion fro m sandimmune asopressin to 
asopressin Neoral in stable liver transplant patien ts. Transplant Proceed 30: 1852 -1853, 1998.  
  
35. Hashmonai M, Kopelman D, Asalia A, Kl ein Y, Bahous H. and Baruch Y.  Extensive liver 
Resections: report of 72 cases. Harefuah 135: 409 -413, 1998.  
  
36. Hoffman R, Assy N, Brenner B.  and Baruch Y.  Factor five Leiden mutation and Budd Chiari 
Syndrome report of six patients. Liver transplant a nd surg 5:96 -100, 1999.  
  
37. Baruch Y , Assy N, Weisbuch F, Reisner S Gaitini D, Blendis L, Enat R, Bomzon A.  
A pilot Study on the hemodynamic effect of short te rm ursodeoxycholic acid therapy in patients 
with Stable liver cirrhosis. Amer J Gastroenterol 9 4: 3000 -3004, 1999.  
  
38. Eisenman A, Armali Z, Enat R, Bankir L, Baruch Y.  Low -Dose 12 asopressin reverse renal Shut 
down both in patients with the hepatorenal syndrome  and in patients with end stage heart  
Failure. J Intern Med 246: 183 -190, 1999.  
  
39. Paradis K et al (multiple authors). Prospective, multi -center study of patients treate d with living   
Pig tissue: is there an evidence of cross species t ransmission of porcine endogenous retrovirus?  
Science 285: 1236 -1241, 1999.  
  
40. Ben -Ari Z, Samuel D, Zemel R, Baruch Y , Gigou M, Sikuler E, Tur -Kaspa R. Non A  
to G Fulminant viral hepatitis leading to liver transplantation. Arch In t Med 160: 388 -392, 2000.  
  
41. Shlomi B, Machtei EE, Oettinger -Barak O, Peled M, Ardekian L, Laufer D, Baruch Y.      
Alveolar bone height in patients after liver transp lantation. Transplant Proceed 32: 718 -720, 2000.  
  
42. Ben -Ari Z, Baruch Y , Tur -Kaspa R, Fainaru M. Basal and post -methionine serum Homocysteine 
and lipoprotein abnormalities in-patients with prim ary biliary cirrhosis. 
J Invest Med 49: 325 -329, 2001.  
  
43. Oettinger -Barak O, Barak S, Ardekian L, Baruch Y , Peled M, Laufer D, Machtei EE.  
Periodontal changes in liver cirrhosis and post liv er transplantation patients I: Clinical changes.  
J Periodontal 72: 1236 -1240, 2001.  
  
44. Barak S, Machtei EE, Oettinger -Barak O, Peled M, Ardekian L, Laufer D, Baruch Y . 
Alveolar bone height in patients after liver transp lantation. Transplant Proceed, 32: 718 -720, 2000.  
  
45. Segal E, Baruch Y , Kramsky R, Raz B, Ish -Shalom S. Vitamin D deficiency in liver transplant 
patients in Israel. Transplant Proceed 33: 2955 -2956, 2001.  
  
46. Nakhoul F, Gelman R, Green J, Khankin E, Baruch Y .  Lamivudine therapy for severe acute 
hepatitis B virus infection after renal transplanta tion: case report and literature review. Transpla nt   
13  
 Proceed 33: 2948 -2949, 2001.  
 
47.   Oettinger -Barak O, Barak S, Ardekian L, Baruch Y , Peled M, Krivoy N, Laufer D, Machtei EE.  
Periodontal changes in liver cirrhosis and post liv er transplantation patients II: Radiographic change s. J 
Periodontol 73 (3) : 313 -316, 2002.  
  
48. Segal E,  Baruch Y,  Kramsky R, Raz B, Tamir A, Ish-Shalom S. 
Predominant Factors Associated with Bone Loss in Li ver Transplant Patients – after prolonged post 
transplantation period. J. Clinical Transplantation  17: 13-19, 2003. 
  
49. Eisenberg E, Konopniki M, Veitsman E, Kramskay R, G aitini D, Baruch Y.  
Prevalence and Characteristics of Pain Induced by P ercutaneous Liver Biopsy. 
Anesth Analg 96:1392 -1396, 2003.  
  
50. Baruch Y , Neubauer K, Wilfing T, Lorf T, Borcholt M, Ramado ri G. Von -Willebrand  
Immunostaining and mRNA expression in acute and chr onic liver disease.  
Hepatogastroenterology 51: 684 -688, 2004.  
  
51. Gaitini D, Baruch Y , Ghersin E, Kerner H, Shalem B, et al. Feasibility study of ultrasonic fatty liver 
biopsy: texture vs. attenuation and backscatter. Ul trasound Med Biol. 30:1321 -1327, 2004.  
  
52. Farber E, Fisher D, Eliakim R, Beck -Razi N, Angel A, Veitsman E, Chermesh I,  
Yassin C, Gaitini D, Libas M, Soboh S, Baruch Y . Barium Esophagogram (BE) versus Upper 
Endoscopy (EGD) for the screening of esophageal var ices (EV) in patients with compensated cirrhosis 
– a blinded prospective study. Radiology, 237:535 -540, 2005.  
  
53. Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, Gane E, Frie d MW, Chow 
WC, Paik SW, Chang WY, Berg T, Flisiak R, McCloud P , Pluck N; Peginterferon Alfa-2a HbeAg-
Positive Chronic Hepatitis B Study Group ( Baruch Y,  part of study group). Peginterferon Alfa-2a, 
lamivudine, and the combination for HbeAg-positive chronic hepatitis B. N Engl J Med 352:2612-
26 95, 2005.  
  
54. Gaitini D, Lederman M, Baruch Y , Ghersin E, Veitsman E, Kerner H, Shalem B, Yaniv G, Sarfaty C, 
Azhari H. Computerised analysis of liver texture wi th correlation to needle biopsy. Ultraschall 
Med.26:197 -202, 2005.  
  
55. Zalts R, Hayek T, Baruch Y , Nakhoul F, Miller B. Vogt -Koyanagi -Harada syndrome 
associated with renal failure: a case report. J Nep hrol. 19:225 -22 8, 2006.  
  
56. Lurie Y, Landau D, Blendis L, Baruch Y , Veitsman E, Ackermann Z, Halpern Z, Zelberger -Sagie, 
Oren R. Acute hepatitis C in Israel – A Predominant ly Iatrogenic Disease? 
J Gastroenterol Hepatol. 22:158 -164, 2007.  
  
57. Katz D., Cohen M., Kramski R. and Baru ch Y.  Stress in family caregivers of liver transplant 
recipients. Progress in Transplantation. 17:48 -53, 2007.  
  
58. Oettinger-Barak O, Segal E, Machtei EE, Barak S, Baruch Y , Ish-Shalom S. Alveolar bone loss in 
liver transplantation patients: relationship with p rolonged steroid 
treatment and parathyroid hormone levels. J Clin Pe riodontol 34: 1039–1045; 2007. 
  
59. Assy N,  Pruzansky Y, Gaitini D, Shen Orr Z, Hochbe rg Z, and  Baruch Y .  
Growth hormone-stimulated IGF-1 generation in cirrh osis r eflects hepatocellular dysfunction.                     
J Hepatology, 49:34-42, 2008. 
  
60. Zeuzem S, Sulkowski MS, Lawitz EJ, Rustgi VK, Rodri guez-Torres M, Bacon BR, Grigorescu M, 
Tice AD, Lurie Y, Cianciara J, Muir AJ, Cronin PW, Pulkstenis E, Subramanian GM, McHutchison 
JG; ACHIEVE-1  Study Team , ( Baruch Y,  part of study Team).Albinterferon Alfa-2b was not 
inferior to pegylated interferon- α in a randomized trial of patients with chronic hep atitis C virus   
14  
 genotype 1. Gastroenterology.139:1257-1266, 2010.  
  
 
61. Nelson DR, Benhamou Y, Chuang WL, Lawitz EJ, Rodrig uez-Torres M, Flisiak R, Rasenack JW, 
Kryczka W, Lee CM, Bain VG, Pianko S, Patel K, Cron in PW, Pulkstenis E, Subramanian GM, 
McHutchison JG; ACHIEVE-2/3 Study Team , ( Baruch Y,  part of study Team). Albinterferon Alfa-
2b was not inferior to pegylated interferon- α in a randomized trial of patients with chronic hep atitis C 
virus genotype 2 or 3. Gastroenterology. 139: 1267- 1276, 2010. 
  
62. R. Kramskay, A. Tansky,  E. Eisenberg, E. Veitsman and Y. Baruch.  
Prophylactic analgesia before percutaneous liver bi opsy (Clinical comparative study). Europen.  Eur J 
Gastroenterol Hepatol. 23: 782-786, 2011. 
  
63. Jacobson IM, McHutchison JG, Dusheiko G, Di Biscegl ie AM, Reddy KR, Bzowej NH, Marcellin P, 
Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M , Shouval D, Sola R, Terg RA, Yoshida EM, Adda 
N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Ka uffman RS, Zeuzem S; ADVANCE Study  
Team  (Baruch Y,  part of study Team).  Telaprevir for previously un treated chronic hepatitis C virus 
infection. N Engl J Med. 23; 2405-2416, 2011. 
  
64. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Rob erts S, Focaccia R, Younossi Z, Foster GR, 
Horban A, Ferenci P, Nevens F, Müllhaupt B, Pockros  P, Terg R, Shouval D, van Hoek B, Weiland O, 
Van Heeswijk R, De Meyer S, Luo D, Boogaerts G, Pol o R, Picchio G, Beumont M; REALIZE Study 
Team  (Baruch Y,  part of study Team) .Telaprevir for retreatment of  HCV infection. N Engl J Med. 
23: 2417-2428, 2011. 
  
65. E. Veitsman, E. Shahar, G. Hassoun,  M. Lorber , R.  Kramskay, C. Maor , S. Pollack  and  Y. Baruch . 
Outcome of treatment with Peg–Interferon  and Ribav irin in HIV-HCV co-infected patients: "REAL 
LIFE" single center experience. Harefuah. 151(12):6 84-687, 721, 720, 2012. 
  
66. E. Machtei, M. Falah, O. Oettinger-Barak, Y. Baruch  and  J. Horwitz. 
Periodontal status in post liver transplantation pa tients – 10 years follow-up.                              
Quintessence Int.43(10):879-885, 2012. 
  
67. M. Woynarowski, A. Nemeth, Y. Baruch , S. Koletzko, M. Melter, B. Rodeck, C. Strassburg,  M. Pröls, 
M. Wo źniak, MP. Manns and the European AIH-BUC-Study Grou p. 
Budesonide versus prednisone in combination with az athioprine for the treatment of autoimmuner 
hepatitits in adolescents: results of an internatio nal randomized trial. J Pediatr.163(5):1347-1353, 2 013. 
 
68. Ferenci P, Bernstein D, Lalezari J, Cohen D, Luo Y,  Cooper C, Tam E, Marinho RT, Tsai N, Nyberg 
A, Box TD, Younes Z, Enayati P, Green S, Baruch Y , Bhandari BR, Caruntu FA, Sepe T, Chulanov 
V, Janczewska E, Rizzardini G, Gervain J, Planas R,  Moreno C, Hassanein T, Xie W, King M, 
Podsadecki T, Reddy KR.  ABT-450/r-Ombitasvir and D asabuvir with or without Ribavirin for HCV.  
N Engl J Med. 22;370(21):1983-1992, 2014. 
  
69. Manns MP, Vierling JM, Bacon BR, Bruno S, Shibolet O, Baruch Y , Marcellin P, Caro L, Howe AY, 
Fandozzi C, Gress J, Gilbert CL, Shaw PM, Cooreman MP, Robertson MN, Hwang P, Dutko FJ, Wahl 
J, Mobashery N. The Combination of MK-5172, Peginte rferon, and Ribavirin is Effective in 
Treatment-Naive Patients with Hepatitis C Virus Gen otype 1 Infection Without Cirrhosis. 
Gastroenterology.147(2):366-376, 2014.  
  
 
 
 
Case Reports 
 
70. Baruch Y , Levi Y, Brook JG, Kleinhaus U, Hashmonai M.  Splenic abscess diagnosed by the 
aid Of abdominal computerized tomography: report of  2 cases.  Br J Surg 68:137 -138, 1981.    
15  
   
71. Levi Y,  Aviram M, Baruch Y , Brook JG.  Familial hypercholesterolemia and 
Hyperlipoproteinemia, type III.  Harefuah 106:565 -566, 1984 (in Hebrew).  
  
72. Enat R, Baruch Y , Malberger E, Caftori I.  Diagnosis of parathyroid cyst with hormonal 
activity.  Harefuah 103:399 -400, 1987 (in Hebrew).  
  
73. Baruch Y , Levi Y, Goldstein D, Monichor M, Eidelman S.  Massive haematemesis: presenting  
Symptoms of cystadenocarcinoma of the pancreas.  Po stgrad Med J , 65:42 -44, 1989.  
  
74. Naschitz JE, Enat R, Yeshurun D, Eisenberg D, Baruch Y , Bassan L, Misselevitch I, Boss H.   
Massive subcapsular fibrosis of the liver: ultrason ic and computerized tomographic 
characteristics. J Clin Gastroenterol 13:470 -474, 1991.  
  
75. Baruch Y , Weiner N, Ronen N, Enat R, Blumenfeld Z.  Pregnancy after liver transplantation.  
Int J Gynecol Obstet 41:273 -276, 1993.  
  
76. Eisenman A, Baruch Y , Shechter Y, Oren I.  Blood exchange: a rescue pro cedure for 
complicated Malaria falciparum. Vox Sang 68:19 -21, 1995.  
  
77. Baruch Y , Weitzman E, Markiewicz W, Eisenman A, Eid A, Enat  R. Severe fluid retention and 
cardiomyopathy in a liver transplant patient on FK5 06.Transplant Proceed. 28: 2250 -2251, 1996.  
  
78. Assy N, Rosenthal E, Hazani A, Etzioni A, Baruch Y . Human parvovirus B19 infection  
associated with idiopathic thrombocytopenic purpura  in a child following liver transplantation.  
J Hepatol 27: 934 -936, 1997.  
  
79. Edoute Y, Baruch Y , Lachter J, Furman E, Bassan L, Assy N. Severe cholestatic jaundice 
induced by Epstein-Barr virus infection in the elde rly. J Gastroenterol Hepatol 13: 821-824, 
1998.  
  
80. Ben Ari Z. Broida E, Monselise Y, Kazatsker A, Baruch Y, Pappo O, Skappa E, Tur -Kaspa R. 
Syncytial giant-cell hepatitis due to autoimmune he patitis type III (LKM1+) presenting as 
subfulminant hepatitis. Am J Gastroenterol 95: 799 -801, 2000.  
  
81. Armali Z, Bergman R, Bassan L and Baruch Y . Skin granuloma; unusual presentation of 
Recurrence of primary biliary cirrhosis after liver  transplantation.  
Transplant Proceed 32: 717, 2000.   
  
82. Veitsman E., Yigla M., Thaler I. and Baruch Y . Two successful pregnancies in a patient 
with advanced liver cirrhosis and hepatopulmonary s yndrome.  
Gastroenterology and Hepatology, 3: 546 -550, 2007.  
  
83. Saadi T, Rosenbaum H, Veitzman E. and Baruch Y . Gaucher's disease Type I - a 
disease masked by the presence of abnormal laborato ry tests common to primary liver 
disease. European Journal of Gastroenterology & Hep atology. Eur J Gastroenterol 
Hepatol 
  
84. Saadi T, Khoury S, Veitsman E, Baruch Y , Raz-Pasteur A. Spontaneous bacterial 
peritonitis with a very high leukocyte count in asc itic fluid caused by haemophilus 
influenza. Int J Gen Med. 19;6:689-691, 2013. 
  
85. Saadi T, Waterman M, Yassin H, Baruch Y . Metformin-Induced Mixed hepatocellular 
and cholestatic hepatic injury – case report and li terature review. Int J Gen Med.  
19;6:703-706, 2013. 
  
86. Saadi T, Brun R, Chowers Y, Baruch Y , Waterman M. Recurrent small intestinal ileus   
16  
 secondary to valsartan treatment. J Clin Gastroente rol.48(5):462-463, 2014. 
  
87. Safadi R. Konikoff  F. Mahamid M. Zelber-Sagi S. Ha lpern M. Gilat T. Oren R. and the 
FLORA Group. The Fatty Acid–Bile Acid Conjugate Ara mchol Reduces Liver Fat 
Content in Patients With Nonalcoholic Fatty Liver D isease . Clinical Gastroenterology 
and Hepatology, 2014. 
 
Review papers 
 
88. Baruch Y , Aviram M, Brook J.G.  hyperlipidemia in liver dis ease.  Harefuah 104:61 -64, 
1983  (In Hebrew).  
  
89. Baruch Y , Eidelman S.  The treatment of biliary cirrhosis.  Harefuah 106:186 -187, 1984  
(In Hebrew).  
  
90 . Baruch Y , Engel A, Enat R. Transjugular liver biopsy: how a nd when.  Harefuah 
119:338 -339,  1991 (In Hebrew).  
  
91 . Baruch Y, Medicine Oncolgy , Forum Media, A. Kotten ed. p. 26 0 -261, May 2008 (In 
Hebrew).  
  
92 . Makhoul B., Baruch Y . Autoimmune Hepatitis, diagnosis and treatment.  
Harefuah update Gastroenterology, vol 1:33 -38, 2011 ( In Hebrew).  
  
93.  Sikuler E, Ackerman Z, Braun M, Baruch Y , Bruck R, Safadi R, Shlomai A, Ben-Ari Z; 
Guidelines for diagnosis and management of cirrhoti c ascites and its complications. The 
Israeli Association for the Study of the Liver. Har efuah.151(12):705-8, 719, 2012 (In 
Hebrew). 
  
94.  Zuckerman E, Safadi R, Oren R, Shibolet O, Baruch Y , Bruck R, Lurei Y, Kaspa RT, 
Abu-Mouch S, Shouval D, Ben-Ari Z; Israeli guidelin es for the treatment of chronic 
hepatitis C infection--2012 Israeli Association for  the Study of the Liver.  
Harefuah. 151(12):709-14, 719, 2012 (In Hebrew). 
 
Books and book chapters 
 
95. Ivanetich K, Thumser AEA, Ziman MR, Baruch Y , Kirsh RE.  Liver injury and regeneration.  
In: Arias IM, Frenkel M, Wilson JHP (eds).  The Liv er Annual No. 5.  Elsevier, Amsterdam, 
pp 71 -115, 1985.  
  
96. Baruch Y , Brandes JM, Berk PD.  Bilirubin metabolism, diseases of altered bilirubin  
metabolism, And pregnancy.  In: Medical, Surgical, and Gynecologic Complications of 
Pregnancy, 5th ed.Williams & Wilkins, Baltimore, chap. 53, 863 -902, 1991.  
  
97. Oettinger -Barak O, Barak S, Baruch Y  and Machtei EE.  Periodontal Status of Liver 
Cirrhosis and Post Transplantation Patients.  In “P rogress in Liver Cirrhosis Research".  
Nova Science Publishers, Inc. 2005.   
  
98. Baruch Y .  Liver diseases in the elderly. In "The gastroint estinal tract in the aged". 
Stephen Malnick,  Ehud Melzer Sari Tal, Eds. NOVA P ublishers 2011.  
  
99. Baruch Y . The Liver Vascular Bed for  Tissue Engineering. I n "Regenerative Medicine 
and Tissue Engineering; From Cells to Organs". InTe ch - Open Access Publisher, D. 
Eberli editor, 449 -462, 2011.  
 
Letters to the Editor 
   
17  
 100 . Edoute Y, Kaplan J, Ben -Haim SA, Baruch Y .  Haemoperitoneum induced by fine -
needle aspiration of liver in patients with dissemi nated intravascular coagulation.   
Lancet 339:121 -122, 1992.  
  
101 . Baruch Y , Ben -Porath E, Enat R.  Immunoprophylaxis with hepatitis  B immunoglobulin 
after Liver transplantation: an economical approach . J Hepatol 20:153 -154, 1994.  
  
102 . Krivoy N, Azam M, Baruch Y , Elroi G. Severe cholestasis due to oral hypoglyce mic 
drug. Dia betes care 19:385 -386, 1996.  
  
103 . Modan B,  Baruch Y , Sikuler E, Shouval D.  Need for liver transplantation.  
Lancet 348: 62 -63, 1996.  
  
104 . Baruch Y , Sikuler E., International ascites club – guidelines for the treatment of ascites.  
Harefuah 138: 903 -904, 2000.  
  
105 . Hoffman R, Mahajana A, Agmon P, Baruch Y , Brenner B. Successful use for 
recombinant activated factor VII (Novoseven) in con trolling severe intra abdominal 
bleeding after liver needle biopsy. Thromb Haemost 87:346 -347, 2002.  
  
Editorials: 
 
106. Baruch Y . The liver: a large endocrine gland. J Hepatology 32: 505 -507, 2000.  
 
 
16.  CONFERENCES : 
 
Organizing committee of international medical and n ational conference 
 
1. First joint Spanish -Israeli meeting on liver and biliary diseases, Jerusalem, November 1991.  
  
2. European Association for the Study of the Liver, Je rusalem, 1996.  
  
3. First Israeli conference on HIV -HCV co -infection, Tel -Aviv, May 2004.  
 
Plenary or invited talks 
 
1. HBeAg negative chronic hepatitis B.  
BMS satellite symposium. EASL, Berlin, April 2004.  
  
2. Hydatid liver disease. World Congress of Gastroente rology, Montreal, September 2005.  
 
Abstracts 
 
1. Yeshurun D, Aviram M, Barak K, Baruch Y , Brook JG.  The effect of prolonged fasting on  
Lipoprotein concentration and composition in obese women.  Isr J Med Sci 18:538, 1982.  
  
2. Baruch Y , Aviram M, Eidelman S, Brook JG.  Dyslipoproteinem ia in patients with primary  
Biliary cirrhosis.  Sixth International Symposium o n Atherosclerosis, Berli n, June 1982.  
  
3. Aviram M, Baruch Y , Viener A, Brook JG.  Platelet aggregation in hype rcholesterolemia:  
A comparison between familial hypercholesterolemia and primary biliary cirrhosis.  
Third International Austrian Atherosclerosis Confer ence, Vienna,  April 1983.  
  
4. Baruch Y , Aviram M, Brook JG.  Increased plasma high -density lipoprotein in patients with  
Primary biliary cirrhosis.  Twenty-fourth Internati onal Conference on the Biochemistry of  
lipids, Toulouse, France, September 1983. 
 
5. Baruch Y , Terblanche J, Kirsch RE.  Hepatic regenerative factor.  S Afr Med J 65:1024 -1025,    
18  
 1984.  
 
6. Baruch Y .  Liver regeneration.  In: Kirsch RE, Kruskal J, C somos S, Terblanche J (eds).  
Liver Update: Proceedings of an International Sympo sium on Liver Physiology and Disease,  
Vol. 2. Balliere Tindall, Cape Town, pp 121 -122, 1985.  
  
7. Baruch Y , Enat R, Gershoni -Baruch R, Ben -Porath E.  Can booster effect of HBV vaccine given 
To cirrhotic patients identify previous infection w ith hepatitis B virus?   
J Hepatol 7 (suppl 1): 593, 1988.  
  
8. Liang TJ, Ben -Porath E, Enat R, Baruch Y , Rimon N, Brown NV, Blum HE, Wands JR.   
Detection of hepatitis B-related virus in-patients with idiopathic liver disease.  Annual meeting 
Of the American Association for the S tudy of Liver Diseases, Chicago, October 1989.  
  
9. Baruch Y , Liang TJ, Enat R, Rimon N, Wands JR, Ben -Porath E. Anamnestic immunologic  
Response to HBV vaccine in cirrhotic patients.  Int ernational Symposium on Viral Hepatitis and  
Liver Disease, Houston, Texas, April 1990.  
  
10. Hochberg Z, Baruch Y , Bick T, Hertz P, Amit T.  Common expression and regulation of the  
Growth hormone receptor and GH binding protein in h uman and rat.   
Twenty -ninth meeting of  ESPE, Vienna, September 1990.  
  
11. Baruch Y , Amit T, Enat R, Hochberg Z.  Growth hormone -binding protein in the evaluation of  
Liver cirrhotic patients.  J Hepatol (Suppl 2), 11: S73, 1990.  
  
12. Blumenfeld Z, Baruch Y , Brandes JM.  New applications for GnRH analogues: dysfunctional  
Bleeding in women after liver transplantation and e ndometrial hyperplasia.  Second International 
Symposium on Analogues in Cancer and Human Reproduc tion, Geneva, November 1990.  
  
13. Baruch Y , Blumenfeld Z, Brandes JM, Enat R.  Dysfunctional bleeding in women after liver  
Transplantation and endometrial hyperplasia: use of  GnRH analogue.  International Meeting on  
Transplant Monitoring, Jerusalem, June 1991.  
  
14. Baruch Y , Enat R, Neufeld G.  The effect of basic fibroblast growth factor (Bfgf)  on liver  
Regeneration after partial hepatectomy.  J Hepatolo gy 13:S95, 1991.  
  
15. Baruch Y , Nesher S, Ben -Porath E, Enat R.  Incidence of anti -HCV in patients with chronic 
liver Disease in Israel.  Fifteenth world congress of the Israel Medical Association, Jerusalem, 
November 1991.  
  
16. Baruch Y , Diab S, Blumenfeld Z, et al.  The Rambam experien ce with post liver transplantation  
Care. First joint Spanish -Israeli meeting on liver and biliary disease, Jerusalem, April 1992.  
  
17. Baruch Y , Amit T, Enat R, Shoshany G, Hochberg Z.  The role of the liver in determining  
GH -binding protein.  J Hepatol 16(suppl 1):S65, 1992.  
  
18. Baruch Y , Assy N, Amit T.  IGF -BP 3 and IGF -I generation following  growth hormone  
Stimulation as a liver endocrine reserve test.  Hep atology 20:330A, 1994.  
  
19. Baruch Y , Assy N, Reisner S, Blendis LM, Berry E, Enat R, B omzon A.  Plasma antioxidant  
Activity (PTAA) and cardiovascular (CVS) function f ollowing UDCA treatment in PBC. 
J Hepatol 23:209, 1995.  
  
20. Eisenman A, Armali Z, Enat R, Baruch Y . Low dose Vassopressin (LDVP) reverses renal  
Shut-down both in patients with hepatorenal syndrom e and in those with end stage heart failure. 
J Hepatol; 98: 1997.  
  
21. Baruch  Y, Ben -Porath E, Salomonov A, Heidi S, Enat R, Lapidot A, Rimon N,  
Satinger Y, Weisbuch F and Baruch Y. Is the andomiz e use of Interferon to treat    
19  
 chronic HCV infection in Israel is justified. J Hep atol; 157, 1997.  
  
22. Baruch  Y, Krasik A, Shoshany G, Shenkar L, Assy Y, Paizi M, Kraizer Y, Spira G.  
Vascular endothelial growth factor (VEGF) promotes parenchymal liver cell growth in Vivo. 
EASL, Lisbon April 1998.  
  
23. Peretz A, Baruch Y , Spira G and Cohen S. Fabrication of alginate comp osit e containing VEGF  
To enhance scaffold vascularization. Los -Angeles June 1998.  
  
24. Assy Y, Pruzansky Y, Gaitini D, Hochberg Z, Enat R,  Baruch Y . Changes in insulin -like  
Growth factor-I release after GH administration in patients with different grades of liver 
Cirrhosis. Hepatology, abs. 889: 1998.  
  
25. Baruch Y , Neubauer K, Wilfing T, Lorf T, Borcholt M, Ramado ri G.  
Von-Willebrand Immunostaining and mRNA expression i n acute and chronic liver disease.  
Hepatology 1998, abs. 1887.  
  
26. Ben Ari Z, Baruch Y , Grenberg A, Levi N, Tur -Kaspa R. Basal and postmethionine load And 
plasma homocysteine levels in -patients with chronic liver disease. J Hepatol Supp l 1 30:1999.  
  
27. Assy N, Kraizer Y,  Baruch Y , Dabbach B, Spira G. Vascular endothelial growth factor  
And respective monoclonal antibodies can modulate l iver cell proliferation following partial 
Hepatectomy in rats. Hepatology 30:61A, 1999.  
  
28. Baruch Y , Barak S, Machtei EE, Oettinger -Barak O, Peled M, Ardekian L, Laufer D.  
The effect of liver disease and liver transplantati on on alveolar bone height.  
Hepatology 30: 665A, 1999.  
  
29. Weitzman E, Shenkar L, Shoshany G, Kasinetz L, Gers honi -Baruch R, Baruch Y.  
Detection of transplanted hepatocytes by semi-quant itative analysis, using PCR and FISH for the 
sry region on the Y -Chromosome. Hepatology 188A, October 1999.  
  
30. Tassopoulos N, Hadziyannis S, ldeo G, Jurewicz R, Y oung C, Saltzman R, Trepo C, Bonino F. 
for the Famciclovir Anti-HBe + Chronic Hepatitis B Study Group.  
Famciclovir treatment of Anti-HBe positive chronic hepatitis B results of a randomised, placebo-
controlled study.  EASL, Rotterdam, May 2000.  
  
31. Oettinger -Barak O, Barak S, Ardekian L, Baruch Y , Laufer D, Machtei EE.  
Gingival and radiographic changes in Tacrolimus ver sus Cyclosporine-A treated patients.  
J Dent Res (Suppl.) 2000.  
  
32. Perets A, Cohen S, Wiesbuch F, Shenkar L, Shoshany G, Neufeld G, Baruch Y . 
Alginate composites containing vascular growth fact ors enhance scaffolds angiogenesis as a first 
step before hepatocyte transplantation. AASLD, Dallas, N ovember 2001.  
  
33. Baruch Y , Neubauer K, Shenkar L, Ramadori R. Von Willebrand  Factor expression and plasma 
levels after partial hepatectomy in the rat. EASL P rague, April 2001. 
(Selected as a represent ative work for 2001 by the EASL scientific committe e).  
  
34. Shani H, Tsiperson V, Shoshany G, Veitzmen E.  Neufeld G, Baruch Y .  
The effect of VEGF on hepatocyte engraftment after intrasplenic cell transplantation in the rat.  
EASL, Madrid 2002.  
  
35. Tsiperson V., Ilan N, Shoshany G ,  Goldshmidt O, Vlodavsky V, Baruch Y.   
The effect of Heparanase on hepatocyte engraftment after intrasplenic cell 
transplantation in the rat. EASL, Istanbul, April 2 003.  
  
36. Farber E, Fisher D, Eliakim R, Beck -Razi N, Angel A, Veitsman E, Chermesh I,  
Yassin C, Gaitini D, Libas M, Soboh S, Baruch Y . Barium Esophagogram (BE) versus Upper   
20  
 Endoscopy (EGD) for the screening of esophageal var ices (EV) in patients with compensated 
cirrhosis – a blinded prospective study.  AASLD, Boston, October 2003.  
  
37. Shani H, Tsiperson V, Shoshany G, Veitzmen E. Neufe ld G, Baruch Y .  
The effect of VEGF on hepatocyte engraftment after intrasplenic cell transplantation in 
the rat. AASLD, Boston,  October 2003 . 
  
38. Baruch Y , Boyanjo I, Tsiperson V, et al.  Heparanase and hV EGF 165  increase intravascular 
survival of transplanted Hepatocytes and EC prolife ration in rats after partial hepatectomy, ILTS, 
Rio -de Janeiro, June 2007. Liver Transplantation 13:510 4, 2007 (Abs 147).  
  
39. Carmel J, Arish A, Ilan N, Shoshany  G, Vlodavsky I,  Baruch Y . Heparanase stimulates 
hepatocytes and sinusoidal endothelial cell prolife ration in the rat early and late after partial 
hepatectomy . Sun Francisco, AASLD 2008.  
  
40. Veitsman E, Edoardo S, Hassoun G, Lorber M, Maor K,  Kramskay R, Pollack S,  
Baruch  Y.  High sustained virological response to peg-inter feron and ribavirin in HIV-HCV co-
infected patients: "real life" single center experi ence.  San Francisco, AASLD 2008.  
  
41. R. Kramskay, A. Tansky, E. Eisenberg, E. Veitsman a nd Baruch Y . 
Prevention of Pain and Anxiety Associated with Perc utaneous Liver Biopsy: A 
Randomized Study. EASL Vienna, Austria 2010. 
  
42. T. Saadi, A. Arish, J. Carmel, Z. Bramnik, O. Naysh ool, I. Mironi-Harpaz, D. Seliktar,  
Baruch Y . Hepatocyte cell line function in a biosynthetic h ydrogel scaffold for liver 
tissue engineering. EASL Vienna, Austria 2010. 
  
43. J. Carmel, A. Arish, N. Ilan, G. Shoshany, I. Vloda vsky and Baruch Y.  
Heparanase accelerates proliferation of both hepato cytes and sinusoidal endothelial cells 
after partial hepatectomy despite IL-6 and TNF-a do wn regulation.  EASL Vienna, 
Austria 2010. 
  
44. Pianko S, Lurie Y, Baruch Y , Leggett B, Hughes B, Shouval D, Crawford D, Bell S,      
et al; Final results of ACHIEVE-1: albinterferon al fa-2b plus ribavirin in treatment-naïve 
patients with genotype 1 chronic hepatitis C. APASL  Beijing 2010. 
  
45. M. Woynarowski, A. Nemeth, Baruch Y , S. Koletzko, M. Melter, B. Rodeck, C. 
Strassburg, M. Prols, MP. Manns, and the European A IH-BUS-Study Group.    
Budesonide 3 mg tid in the treatment of autoimmune hepatitis (AIH) in adolescents, a 
subgroup analysis of the European AIH-BUS-Study. EA SL Berlin 2011. 
  
46. Baruch Y .  Liver Tissue engineering, International Hepatobi liary, Pancreatic and 
transplantation surgery (IHPB). Jerusalem, May 2011 . 
  
47. B. Makhoul, E. Weitzman. M. Libes and Y. Baruch . Low Incidence of Liver Damage in 
Non Alcoholic High Risk Patients with Psoriasis Exp osed to High Dose Methotrexate. 
San Francisco, AASLD 2011 . 
  
  
48. O. Nayshool, J. Carmel, T. Saadi, A. Arish, Z. Bram nik ,  I. Mironi-Harpaz, D. Seliktar, 
Y. Baruch . Microcapsules made of biosynthetic hydrogel scaff olds, for intravascular 
liver tissue regeneration therapy. San Francisco, A ASLD 2011. 
  
49. J. Carmel, O. Nayshool, T. Saadi, A. Arish, Z. Bram nik ,  U. Kaplan  ,  I. Mironi-Harpaz,   
21  
 D. Seliktar, Y. Baruch . Micro cell-compatible hydrogels, allow for long t erm 
hepatocytes engraftment after intravascular transpl antation. Washington,  AASLD, 
Hepatology 58:4, 2013 (Abs 337). 
  
  
  
  
  
  
 
 